Evaluation of Reference variability [Design Issues]

posted by Nirali  – India, 2009-04-13 13:53 (5912 d 21:54 ago) – Posting: # 3515
Views: 5,042

Dear All,

We want to conduct BE replicate study to demonstrate that the within-subject variability for Cmax of the reference compound in the study is >30% for EU regulatory.

To check reference variablity which study design and model shall be used for statistical analysis?

Shall we use 2-period replicate design to assess the inter and intra-subject variability of reference drug, in which reference drug given in both the periods?

Thanks & Regards,
NIRALI

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
76 visitors (0 registered, 76 guests [including 41 identified bots]).
Forum time: 11:47 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5